

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

These amendments introduce no new matter and support for such is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of any previously claimed subject matter, or agreement with any objection or rejection of record.

Listing of Claims:

1. (Original) A recombinant respiratory syncytial virus (RSV) having an attenuated phenotype and comprising a phosphoprotein (P), which phosphoprotein comprises at least one artificially mutated amino acid residue.
2. (Original) The recombinant RSV of claim 1, wherein the phosphoprotein comprises at least one substituted amino acid residue.
3. (Original) The recombinant RSV of claim 1, wherein the phosphoprotein comprises a deletion of at least one amino acid residue.
4. (Original) The recombinant RSV of claim 1, wherein the phosphoprotein comprises at least one mutated amino acid residue at a position selected from the group consisting of position 172, position 174, position 175 and position 176.
5. (Original) The recombinant RSV of claim 4, wherein the phosphoprotein comprises at least one substituted amino acid residue at a position selected from the group consisting of position 172, position 174, position 175 and position 176.
- 6-12. (Cancelled).
13. (Original) The recombinant RSV of claim 1, wherein the phosphoprotein comprises a deletion of a plurality of amino acid residues selected from residues 172-176.
- 14-17. (Cancelled).

18. (Original) The recombinant RSV of claim **1**, wherein the at least one mutated amino acid residue eliminates a phosphorylation site.

19. (Original) The recombinant RSV of claim **1**, wherein the phosphoprotein comprises at least one substituted amino acid residue, which substituted amino acid residue eliminates a phosphorylation site.

20. (Cancelled).

21. (Currently Amended) The recombinant RSV of claim ~~[[10]]~~**19**, wherein the at least one substituted amino acid residue replaces a serine at one or more positions selected from the group consisting of positions 116, 117, 119, 232 and 237.

22. (Currently Amended) The recombinant RSV of claim ~~[[12]]~~**21**, wherein the phosphoprotein comprises amino acid substitution S116D, amino acid substitution S116A or amino acid substitution S116L, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

23. (Currently Amended) The recombinant RSV of claim ~~[[12]]~~**21**, wherein the phosphoprotein comprises amino acid substitution S117D, amino acid substitution S117A, or amino acid substitution S117R, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

24. (Currently Amended) The recombinant RSV of claim ~~[[12]]~~**21**, wherein the phosphoprotein comprises amino acid substitution S119D, amino acid substitution S119A, or amino acid substitution S119L, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

25. (Currently Amended) The recombinant RSV of claim ~~[[12]]~~**21**, wherein the phosphoprotein comprises amino acid substitution S232A or amino acid substitution S232D, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

26. (Currently Amended) The recombinant RSV of claim ~~[[12]]~~**21**, wherein the phosphoprotein comprises amino acid substitution S237A or amino acid substitution S237D,

or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

27. (Currently Amended) The recombinant RSV of claim ~~[[12]]21~~, wherein substituted amino acid residues replace serines at positions 117 and 119.

28. (Currently Amended) The recombinant RSV of claim ~~[[18]]27~~, wherein the phosphoprotein comprises an amino acid substitution selected from the group consisting of S117A, S117D and S117R and an amino acid substitution selected from the group consisting of S119A, S119D and S119L, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

29. (Currently Amended) The recombinant RSV of claim ~~[[12]]21~~, wherein substituted amino acid residues replace serines at positions 116, 117 and 119.

30. (Currently Amended) The recombinant RSV of claim ~~[[20]]29~~, wherein the substituted amino acid residue at position 116 is selected from the group consisting of alanine (S116A), aspartic acid (S116D) and leucine (S116L), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

31. (Currently Amended) The recombinant RSV of claim ~~[[20]]29~~, wherein the substituted amino acid residue at position 117 is selected from the group consisting of alanine (S117A), aspartic acid (S117D) and arginine (S117R), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

32. (Currently Amended) The recombinant RSV of claim ~~[[20]]29~~, wherein the substituted amino acid residue at position 119 is selected from the group consisting of alanine (S119A), aspartic acid (S119D) and leucine (S119L), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

33. (Currently Amended) The recombinant RSV of claim ~~[[20]]29~~, wherein the phosphoprotein comprises an amino acid substitution selected from the group consisting of S116L, S116A, and S116D; an amino acid substitution selected from the group consisting of S117R, S117A, and S117D; and an amino acid substitution selected from the group

consisting of S119L, S119A, and S119D, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

34. (Currently Amended) The recombinant RSV of claim **[[12]]21**, wherein substituted amino acid residues replace serines at positions 232 and 237.

35. (Currently Amended) The recombinant RSV of claim **[[25]]34**, wherein the substituted amino acid residue at position 232 is selected from the group consisting of alanine (S232A) and aspartic acid (S232D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

36. (Currently Amended) The recombinant RSV of claim **[[25]]34**, wherein the substituted amino acid residue at position 237 is selected from the group consisting of alanine (S237A) and aspartic acid (S237D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

37. (Currently Amended) The recombinant RSV of claim **[[25]]34**, wherein the phosphoprotein comprises an amino acid substitution selected from the group consisting of S232A and S232D and an amino acid substitution selected from the group consisting of S237A and S237D, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

38. (Currently Amended) The recombinant RSV of claim **[[12]]21**, wherein substituted amino acid residues replace serines at positions 116, 117, 119, 232 and 237.

39. (Currently Amended) The recombinant RSV of claim **[[29]]38**, wherein the substituted amino acid residue at position 116 is selected from the group consisting of leucine (S116L), alanine (S116A) and aspartic acid (S116D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

40. (Currently Amended) The recombinant RSV of claim **[[29]]38**, wherein the substituted amino acid residue at position 117 is selected from the group consisting of arginine (S117R), alanine (S117A) and aspartic acid (S117D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.

41. (Currently Amended) The recombinant RSV of claim ~~[[29]]~~38, wherein the substituted amino acid residue at position 119 is selected from the group consisting of leucine (S119L), alanine (S119A) and aspartic acid (S119D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.
42. (Currently Amended) The recombinant RSV of claim ~~[[29]]~~38, wherein the substituted amino acid residue at position 232 is selected from the group consisting of alanine (S232A) and aspartic acid (S232D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.
43. (Currently Amended) The recombinant RSV of claim ~~[[29]]~~38, wherein the substituted amino acid residue at position 237 is selected from the group consisting of alanine (S237A) and aspartic acid (S237D), or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein.
44. (Currently Amended) The recombinant RSV of claim ~~[[29]]~~38, wherein the phosphoprotein comprises an amino acid substitution selected from the group consisting of S116L, S116A, and S116D; an amino acid substitution selected from the group consisting of S117R, S117A, and S117D; an amino acid substitution selected from the group consisting of S119L, S119A, and S119D; an amino acid substitution selected from the group consisting of S232A and S232D; and an amino acid substitution selected from the group consisting of S237A and S237D, or wherein the phosphoprotein is an artificial conservative variation of such a phosphoprotein
45. (Original) The recombinant RSV of claim 1, wherein the recombinant RSV comprises a human RSV of subgroup A, subgroup B or a chimera thereof.
46. (Original) A nucleic acid encoding the recombinant RSV of claim 1.
- 47-52. (Cancelled).
53. (Original) The phosphoprotein of claim 1, or an artificial conservative variation thereof.
54. (Currently Amended) A nucleic acid encoding the phosphoprotein of claim ~~[[39]]~~53.
55. (Original) A live attenuated respiratory syncytial virus vaccine comprising an immunologically effective amount of the recombinant RSV of claim 1.

56-57. (Cancelled).

58. (Original) A method for stimulating the immune system of an individual to produce an immune response against RSV, the method comprising administering to the individual the recombinant RSV of claim **1** in a physiologically acceptable carrier.

59. (Currently Amended) The method of claim ~~[[43]]~~**58**, wherein the immune response is a protective immune response.

60. (Currently Amended) The method of claim ~~[[43]]~~**58**, wherein the recombinant RSV is administered to the upper respiratory tract of the individual.

61-240. (Cancelled)